Mary‐Ellen Taplin
About
Mary‐Ellen Taplin is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology.
According to data from OpenAlex, Mary‐Ellen Taplin has authored 203 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 180 papers in Pulmonary and Respiratory Medicine, 58 papers in Radiology, Nuclear Medicine and Imaging and 51 papers in Oncology. Recurrent topics in Mary‐Ellen Taplin's work include Prostate Cancer Treatment and Research (176 papers), Prostate Cancer Diagnosis and Treatment (54 papers) and Radiopharmaceutical Chemistry and Applications (52 papers). Mary‐Ellen Taplin is often cited by papers focused on Prostate Cancer Treatment and Research (176 papers), Prostate Cancer Diagnosis and Treatment (54 papers) and Radiopharmaceutical Chemistry and Applications (52 papers). Mary‐Ellen Taplin collaborates with scholars based in United States, Canada and United Kingdom. Mary‐Ellen Taplin's co-authors include Steven P. Balk, Howard I. Scher, Glenn J. Bubley, Mohammad Hirmand, Lynn Seely, Johann S. de Bono, Fred Saad, Karim Fizazi, Cora N. Sternberg and Andrew J. Armstrong and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.
In The Last Decade
Mary‐Ellen Taplin
195 papers receiving 9.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mary‐Ellen Taplin United States | 34 | 8.2k | 2.6k | 2.6k | 2.2k | 2.1k | 203 | 9.9k | ||
| Gerhardt Attard United Kingdom | 56 | 8.1k 1.0× | 3.6k 1.4× | 4.4k 1.7× | 3.3k 1.5× | 1.8k 0.8× | 248 | 11.5k | ||
| Paul N. Mainwaring Australia | 36 | 6.9k 0.8× | 2.4k 0.9× | 2.4k 0.9× | 2.7k 1.3× | 1.1k 0.5× | 143 | 9.2k | ||
| Thian Kheoh United States | 38 | 6.2k 0.8× | 1.3k 0.5× | 2.4k 0.9× | 2.3k 1.1× | 1.5k 0.7× | 124 | 7.6k | ||
| David Olmos United Kingdom | 48 | 6.3k 0.8× | 3.2k 1.2× | 3.2k 1.2× | 4.1k 1.9× | 1.0k 0.5× | 233 | 10.4k | ||
| Eleni Efstathiou United States | 41 | 4.7k 0.6× | 2.0k 0.8× | 1.7k 0.7× | 2.4k 1.1× | 913 0.4× | 203 | 7.4k | ||
| B. Yа. Alekseev Russia | 32 | 5.4k 0.7× | 2.2k 0.8× | 2.3k 0.9× | 2.2k 1.0× | 868 0.4× | 316 | 7.7k | ||
| Glenn Liu United States | 46 | 4.9k 0.6× | 2.5k 1.0× | 1.8k 0.7× | 2.8k 1.3× | 665 0.3× | 175 | 8.5k | ||
| Jorge A. García United States | 43 | 6.2k 0.7× | 2.6k 1.0× | 2.4k 0.9× | 2.1k 1.0× | 715 0.3× | 213 | 8.1k | ||
| Mohammad Hirmand United States | 18 | 4.6k 0.6× | 1.2k 0.4× | 1.6k 0.6× | 1.3k 0.6× | 897 0.4× | 38 | 5.2k | ||
| Robert Dreicer United States | 36 | 8.6k 1.0× | 2.5k 0.9× | 2.7k 1.0× | 4.9k 2.2× | 1.2k 0.6× | 188 | 12.8k |
Countries citing papers authored by Mary‐Ellen Taplin
Since
Specialization
Citations
This map shows the geographic impact of Mary‐Ellen Taplin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary‐Ellen Taplin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary‐Ellen Taplin more than expected).
Fields of papers citing papers by Mary‐Ellen Taplin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mary‐Ellen Taplin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary‐Ellen Taplin. The network helps show where Mary‐Ellen Taplin may publish in the future.
Co-authorship network of co-authors of Mary‐Ellen Taplin
This figure shows the co-authorship network connecting the top 25 collaborators of Mary‐Ellen Taplin. A scholar is included among the top collaborators of Mary‐Ellen Taplin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary‐Ellen Taplin. Mary‐Ellen Taplin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ravi, Praful, Lucia Kwak, Andrés Acosta, et al.. (2025). Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer. European Urology. 87(6). 643–650.
2.
Ravi, Praful, Wanling Xie, Himisha Beltran, et al.. (2024). Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer. European Urology Oncology. 8(3). 709–715.
3.
Yang, David D., Leslie K. Lee, James Man Git Tsui, et al.. (2024). AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer. Radiology. 313(1). e240041–e240041.
4.
Fisher, Matthew, Mateus Crespo, Bora Gürel, et al.. (2024). Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer. 12(7). e009368–e009368.
5.
Choudhury, Atish D., Hyewon Hyun, Emma Kelly, et al.. (2024). Patient outcomes after therapy with 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience.. Journal of Clinical Oncology. 42(4_suppl). 87–87.
6.
Hoffman, Richard M., Paul L. Nguyen, Dana E. Rathkopf, et al.. (2024). Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy. International Journal of Radiation Oncology*Biology*Physics. 120(2). S54–S54.
7.
Sumiyoshi, Takayuki, Xiaofei Wang, Evan W. Warner, et al.. (2023). Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. JNCI Journal of the National Cancer Institute. 116(1). 115–126.
8.
Nguyen, Paul L., Marisa Kollmeier, Dana E. Rathkopf, et al.. (2023). FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP). International Journal of Radiation Oncology*Biology*Physics. 117(2). S81–S82.
9.
Braga‐Basaria, Milena, Thomas G. Travison, Mary‐Ellen Taplin, et al.. (2023). Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS ONE. 18(2). e0281508–e0281508.
10.
Mendes, Adrianna A., Jiayun Lu, Harsimar Kaur, et al.. (2022). Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer. 128(12). 2269–2280.
11.
McKay, Rana R., Lucia Kwak, Jett Crowdis, et al.. (2021). Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clinical Cancer Research. 27(13). 3610–3619.
12.
Mostaghel, Elahe A., Brett T. Marck, Orpheus Kolokythas, et al.. (2021). Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. Clinical Cancer Research. 27(21). 6001–6011.
13.
McKay, Rana R., Rebecca Silver, Rachel H. Bhak, et al.. (2020). Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. Prostate Cancer and Prostatic Diseases. 24(1). 210–219.
14.
Sowalsky, Adam G., Huihui Ye, Manoj Bhasin, et al.. (2018). Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Research. 78(16). 4716–4730.
15.
Russo, Joshua W., Ce Gao, Swati S. Bhasin, et al.. (2018). Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Research. 78(22). 6354–6362.
16.
Ferrari, Anna C., Joshi J. Alumkal, Mark N. Stein, et al.. (2018). Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. Clinical Cancer Research. 25(1). 52–63.
17.
Beltran, Himisha, Alexander W. Wyatt, Edmund C.P. Chedgy, et al.. (2017). Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research. 23(22). 6802–6811.
18.
Calagua, Carla, Joshua W. Russo, Yue Sun, et al.. (2017). Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clinical Cancer Research. 23(22). 6812–6822.
19.
McKay, Rana R., Lillian Werner, Elahe A. Mostaghel, et al.. (2016). A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 23(4). 935–945.
20.
Kryukov, Gregory V., Craig M. Bielski, Kaitlin E. Samocha, et al.. (2015). Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clinical Cancer Research. 22(9). 2183–2189.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gerhardt Attard Breakdown of academic impact, for papers by Paul N. Mainwaring Breakdown of academic impact, for papers by Thian Kheoh Breakdown of academic impact, for papers by David Olmos Breakdown of academic impact, for papers by Eleni Efstathiou Breakdown of academic impact, for papers by B. Yа. Alekseev Breakdown of academic impact, for papers by Glenn Liu Breakdown of academic impact, for papers by Jorge A. García Breakdown of academic impact, for papers by Mohammad Hirmand Breakdown of academic impact, for papers by Robert Dreicer